Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jan;31(1):102-7.
doi: 10.1111/j.1365-2036.2009.04125.x.

An analysis of the placebo effect in Crohn's disease over time

Affiliations
Review

An analysis of the placebo effect in Crohn's disease over time

W C Gallahan et al. Aliment Pharmacol Ther. 2010 Jan.

Abstract

Background: Randomized, placebo controlled trials are used to assess the efficacy of therapies for Crohn's disease. The placebo response and remission rates vary among studies.

Aim: To analyse how the placebo response and remission rates in Crohn's trials have changed over time in the era of parenteral biologic therapies.

Methods: A search for randomized, placebo-controlled trials of parenteral biologic therapies for active Crohn's disease was conducted using online databases. The placebo response and remission rates and study week of evaluation were recorded for each trial. The placebo response and remission rates were analysed as functions of publication date and study week of evaluation.

Results: The odds of a placebo-induced remission and response significantly increased as the week of evaluation increased. The placebo remission rate increased significantly with year of publication. Adjusted for week of evaluation, this increase in placebo remission rate over time was no longer significant. The increase in the placebo response over this time period was not statistically significant.

Conclusion: The observed increase in placebo remission rates over time in trials of parenteral biologic therapies in Crohn's disease is explained by longer times to the primary endpoint in more recent trials.

PubMed Disclaimer

LinkOut - more resources